133 related articles for article (PubMed ID: 25609067)
1. Integrating RAS status into prognostic signatures for adenocarcinomas of the lung.
Starmans MH; Pintilie M; Chan-Seng-Yue M; Moon NC; Haider S; Nguyen F; Lau SK; Liu N; Kasprzyk A; Wouters BG; Der SD; Shepherd FA; Jurisica I; Penn LZ; Tsao MS; Lambin P; Boutros PC
Clin Cancer Res; 2015 Mar; 21(6):1477-86. PubMed ID: 25609067
[TBL] [Abstract][Full Text] [Related]
2. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.
Onitsuka T; Uramoto H; Ono K; Takenoyama M; Hanagiri T; Oyama T; Izumi H; Kohno K; Yasumoto K
J Thorac Oncol; 2010 May; 5(5):591-6. PubMed ID: 20150826
[TBL] [Abstract][Full Text] [Related]
6. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
7. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
[TBL] [Abstract][Full Text] [Related]
9. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
10. Clonality status of multifocal lung adenocarcinomas based on the mutation patterns of EGFR and K-ras.
Takamochi K; Oh S; Matsuoka J; Suzuki K
Lung Cancer; 2012 Mar; 75(3):313-20. PubMed ID: 22209037
[TBL] [Abstract][Full Text] [Related]
11. Is K-ras gene mutation a prognostic factor for colorectal cancer: a systematic review and meta-analysis.
Ren J; Li G; Ge J; Li X; Zhao Y
Dis Colon Rectum; 2012 Aug; 55(8):913-23. PubMed ID: 22810479
[TBL] [Abstract][Full Text] [Related]
12. Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.
Raparia K; Villa C; Raj R; Cagle PT
Arch Pathol Lab Med; 2015 Feb; 139(2):189-93. PubMed ID: 24694341
[TBL] [Abstract][Full Text] [Related]
13. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.
Kern JA; Slebos RJ; Top B; Rodenhuis S; Lager D; Robinson RA; Weiner D; Schwartz DA
J Clin Invest; 1994 Feb; 93(2):516-20. PubMed ID: 7906694
[TBL] [Abstract][Full Text] [Related]
14. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma.
Okudela K; Hayashi H; Ito T; Yazawa T; Suzuki T; Nakane Y; Sato H; Ishi H; KeQin X; Masuda A; Takahashi T; Kitamura H
Am J Pathol; 2004 Jan; 164(1):91-100. PubMed ID: 14695323
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
16. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
17. Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.
Russell PA; Barnett SA; Walkiewicz M; Wainer Z; Conron M; Wright GM; Gooi J; Knight S; Wynne R; Liew D; John T
J Thorac Oncol; 2013 Apr; 8(4):461-8. PubMed ID: 23486266
[TBL] [Abstract][Full Text] [Related]
18. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung.
Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ
N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
[TBL] [Abstract][Full Text] [Related]
20. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
